-+ 0.00%
-+ 0.00%
-+ 0.00%

VivoSim Labs presents EUROTOX 2026 data showing NAMkind platform improves prediction of liver, GI toxicity in small molecules, ADCs

PUBT·09/16/2026 12:07:02
Listen to the news
VivoSim Labs presents EUROTOX 2026 data showing NAMkind platform improves prediction of liver, GI toxicity in small molecules, ADCs
  • VivoSim Labs unveiled new clinical benchmark data at EUROTOX 2026, supporting its NAMkind 3D human liver, intestine toxicity platforms.
  • Results showed stronger alignment with observed human safety outcomes in liver, gastrointestinal risk across small molecules, antibody-drug conjugates.
  • Testing differentiated safety liabilities between ADC components, helping isolate whether toxicity stems from payload, linker, off-target exposure.
  • Data also indicated higher hepatotoxicity for trastuzumab deruxtecan versus trastuzumab emtansine, with greater intestinal sensitivity in ileum tissue.
  • Readout strengthens the commercial case for earlier human-relevant safety screening as regulators accelerate a shift away from animal testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160805PRIMZONEFULLFEED9827806) on September 16, 2026, and is solely responsible for the information contained therein.